Neuropsychiatric symptoms in dementia-A role for neuroinflammation?

Brain Research Bulletin

Volumn 108, Issue , 2014, Pages 88-93

  Holmgren, Simon ^a   Hjorth, Erik ^a   Schultzberg, Marianne ^a   Lärksäter, Marie ^b   Frenkel, Dan ^c   Tysen Bäckström, Ann Christine ^b   Aarsland, Dag ^a,d   Freund Levi, Yvonne ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c TEL AVIV UNIVERSITY   (Israel)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Alzheimer's disease; Behavioural symptoms; BPSD; Cerebrospinal fluid; Cytokines; NPSD

Indexed keywords

INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; IL10 PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; ANXIETY DISORDER; APATHY; ARTICLE; CEREBROSPINAL FLUID; COHEN MANSFIELD AGITATION INVENTORY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEMENTIA; DEPRESSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; MULTIPLE LINEAR REGRESSION ANALYSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPSYCHIATRIC SYMPTOM; VERY ELDERLY; COMPLICATION; ENCEPHALITIS; NEUROPSYCHOLOGICAL TEST;

AGED; AGED, 80 AND OVER; CYTOKINES; DEMENTIA; ENCEPHALITIS; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; NEUROPSYCHOLOGICAL TESTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84907495042     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2014.09.003     Document Type: Article

References (42)

1. Arakawa H., Blandino P., Deak T. Central infusion of interleukin-1 receptor antagonist blocks the reduction in social behaviour produced by prior stressor exposure. Physiol. Behav. 2009 Aug 4, 98(1-2):139-146.
2. Azizi G., Mirshafiey A. The potential role of proinflammatory and anti-inflammatory cytokines in Alzheimer disease pathogenesis. Immunopharmacol. Immunotoxicol. 2012 Dec, 34(6):881-895.
3. Ballard C., Gray A., Ayre G. Psychotic symptoms, aggression and restlessness in dementia. Rev. Neurol. (Paris) 1999, 4:S44-S52. 155 Suppl.
4. Ballard C., Corbett A. Management of neuropsychiatric symptoms in people with dementia. CNS Drugs 2010 Sep, 24(9):729-739.
5. Ballard C., Gauthier S., Corbett A., Brayne C., Aarsland D., Jones E. Alzheimer's disease. Lancet 2011 Mar19, 377(9770):1019-1031.
6. Cerejeira J., Lagarto L., Mukaetova-Ladinska E.B. Behavioural and psychological symptoms of dementia. Front Neurol. 2012, 3(73).
7. Cohen-Mansfield J., Billig N. Agitated behaviours in the elderly I. A conceptual review. J. Am. Geriatr. Soc. 1986 Oct, 34(10):711-721.
8. Colton C.A., Wilcock D.M. Assessing activation states in microglia. CNS Neurol. Disord. Drug Targets 2010 Apr, 9(2):174-191.
9. Connor D.J., Sabbagh M.N., Cummings J.L. Comment on administration and scoring of the neuropsychiatric inventory in clinical trials. Alzheimers Dement. 2008 Nov, 4(6):390-394.
10. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994 Dec, 44(12):2308-2314.
11. Eikelenboom P., Hoogendijk W.J.G., Jonker C., van Tilburg W. Immunological mechanisms and the spectrum of psychiatric syndromes in Alzheimer's disease. J. Psychiatr. Res. 2002 Aug, 36(5):269-280.
12. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975 Nov, 12(3):189-198.
13. Frenkel D., Huang Z., Maron R., Koldzic D.N., Hancock W.W., Moskowitz M.A., et al. Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells. J. Immunol. 2003, 171(12):6549-6555.
14. Frenkel D., Puckett L., Petrovic S., Xia W., Chen G., Vega J., et al. A nasal proteosome adjuvant activates microglia and prevents amyloid deposition. Ann. Neurol. 2008 May, 63(5):591-601.
15. Freund-Levi Y., Basun H., Cederholm T., Faxén-Irving G., Garlind A., Grut M., et al. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int. J. Geriatr. Psychiatry 2008 Feb, 23(2):161-169.
16. Freund-Levi Y., Bloniecki V., Auestad B., Tysen Bäckström A., Lärksäter M., Aarsland D: Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week single-centre study. Dement. Geriatr. Cogn. Disord. 2014, 38:234-244.
17. Freund-Levi Y., Hjorth E., Lindberg C., Cederholm T., Faxén-Irving G., Vedin I. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegaD study. Dement. Geriatr. Cogn. Disord. 2009, 27(5):481-490.
18. Freund-Levi Y., Jedenius E., Tysen-Bäckström A.C., Lärksäter M., Wahlund L.-O., Eriksdotter M. Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial. Am. J. Geriatr. Psychiatry 2013 Sep, 10(13):1064-7481.
19. Garlind A., Brauner A., Höjeberg B., Basun H., Schultzberg M. Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients. Brain Res. 1999 Apr.24, 826(1):112-116.
20. Griffin Ws Alzheimer's-looking beyond plaques. Med. Rep. 2011, 3(24).
21. Haran J.P., Buglione-Corbett R., Lu S. Cytokine markers as predictors of type of respiratory infection in patients during the influenza season. Am. J. Emerg. Med. 2013 Mar 4.
22. Holmes C., Cunningham C., Zotova E., Culliford D., Perry V.H. Proinflammatory cytokines, sickness behaviour and Alzheimer disease. Neurology 2011 Jul 19, 77(3):212-218.
23. Kalaria R.N. Risk factors and neurodegenerative mechanisms in stroke-related dementia. Panminerva Med. 2012 Sept, 54(3):139-148.
24. Kitazawa M., Cheng D., Tsukamoto M.R., Koike M.A., Wes P.D., Vasilevko V., et al. Blocking IL-1 signalling rescues cognition, attenuates tau pathology, and restores neuronal â-catenin pathway function in an Alzheimer's disease model. J. Immunol. 2011 Dec15, 187(12):6539-6549.
25. Lindberg C., Chromek M., Ahrengart L., Brauner A., Schultzberg M., Garlind A. Soluble interleukin-1 receptor type II IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease. Neurochem. Int. 2005, 46:551-557.
26. Lyketsos C.G., Sheppard J.M., Steinberg M., Tschanz J.A., Norton M.C., Steffens D.C., et al. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. Int. J. Geriatr. Psychiatry 2001 Nov, 16(11):1043-1053.
27. McGeer E.G., McGeer P.L. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J. Alzheimers 2010 Dis, 19(1):355-361.
28. Morris J.C. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int. Psychogeriatr. 1997, 9(Suppl 1):173-176.
29. Perry R.T., Collins J.S., Wiener H., Acton R., Go R.C. The role of TNF and its receptors in Alzheimer's disease. Neurobiol. Aging 2001 Nov, 22(6):873-883.
30. Planas A.M., Chamorro A. Regulatory T cells protect the brain after stroke. Nat. Med. 2009, 15:138-139.
31. Prince M., Bryce R., Albanese E., Wimo A., Ribeiro W., Ferri C.P. The global prevalence of dementia: a systematic review and meta-analysis. Alzheimers Dement. 2013 Jan, 9(1):63-75.
32. Rubio-Perez J.M., Morillas-Ruiz J.M. A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal 2012, 756357.
33. Rösler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int. J. Clin. Pract. Suppl. 2002 Jun, 127:20-36.
34. Sasayama D., Hattori K., Wakabayashi C., Teraishi T., Hori H., Ota M., et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J. Psychiatr. Res. 2013 Mar, 47(3):401-406.
35. Symons J.A., Young P.R., Duff G.W. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc. Natl. Acad. Sci. U.S.A 1995 Feb28, 92(5):1714-1718.
36. Tobinick E., Gross H., Weinberger A., Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed 2005 Dec31, 8(2):25-35.
37. Vila N., Castillo J., Dávalos A., Esteve A., Planas A.M., Chamorro A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke 2003 Mar, 34(3):671-675.
38. Wuwongse S., Chang RC.-C., Law A.C.K. The putative neurodegenerative links between depression and Alzheimer's disease. Prog. Neurobiol. 2010 Aug, 91(4):362-375.
39. Wyss-Coray T., Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med. 2012 Jan, 2(1):a006346.
40. Xiuzhe W., Zhu M., Hjorth E., Cortés-Toro V., Eyjolfsdottir H., Graff C., et al. Resolution of inflammation is altered in Alzheimer's disease. Alzheimers Dement. 2014, In press.
41. Yamamoto M., Kiyota T., Horiba M., Buescher J.L., Walsh S.M., Gendelman H.E., et al. Interferon-gamma and tumour necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am. J. Pathol. 2007 Feb, 170(2):680-692.
42. Yeh Y.-C., Ouyang W.-C. Mood stabilizers for the treatment of behavioural and psychological symptoms of dementia: an update review. Kaohsiung J. Med. Sci. 2012 Apr, 28(4):185-193.